1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Novartis Looks To Expand Beovu’s Use And Move On From Safety Scare

Diabetic Macular Edema (DME) Filing Possible In 2021

 
• By Andrew McConaghie

New data for a further indication should help Novartis rebuild momentum for competitor to Eylea, but safety concerns could take years to overcome.

Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland.
Forecasts for Beovu have been downgraded after the safety concerns emerged in February

Novartis AG’s Beovu has matched market-leading ophthalmic therapy Eylea in a new Phase III study, part of its efforts to establish the new less frequently dosed therapy.

The topline results from a Phase III non-inferiority study should pave the way for Beovu (brolucizumab) to add diabetic macular...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.